We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
-16.6%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
AUM
$1.04B
AUM Growth
-$3.41M
Cap. Flow
+$220M
Cap. Flow %
21.29%
Top 10 Hldgs %
43.95%
Holding
852
New
247
Increased
177
Reduced
137
Closed
202

Sector Composition

Rank Sector Weight
1 Healthcare 28.69%
2 Financials 13.57%
3 Materials 7.25%
4 Technology 4.61%
5 Industrials 3.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARKK icon
1
ARK Innovation ETF
ARKK
$5.63B
$102M 9.82%
2,550,000
+1,525,000
+149% +$72.6M
SLVM icon
2
Sylvamo
SLVM
$1.53B
$70.3M 6.79%
2,150,000
+195,000
+10% +$8.18M
ESTA icon
3
Establishment Labs
ESTA
$2.68B
$45.5M 4.39%
836,654
+4,467
+0.5% +$284K
ACET icon
4
Adicet Bio
ACET
$76.1M
$35.7M 3.45%
152,736
+58,983
+63% +$13M
SMFG icon
5
Sumitomo Mitsui Financial
SMFG
$159B
$33.5M 3.23%
5,676,605
FTAI icon
6
FTAI Aviation
FTAI
$20.4B
$33.1M 3.19%
2,003,054
+262,407
+15% +$4.65M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$32.9M 3.18%
+2,264,150
New +$33.7M
CUTR
8
DELISTED
Cutera, Inc.
CUTR
$22.4M 2.16%
+596,305
New +$31.5M
RLMD icon
9
Relmada Therapeutics
RLMD
$540M
$20.3M 1.96%
1,066,854
-97,507
-8% -$2.13M
STOK icon
10
Stoke Therapeutics
STOK
$1.81B
$19.9M 1.93%
1,509,620
+89,090
+6% +$1.35M
PSTH
11
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
$19M 1.84%
952,000
+250,000
+36% +$4.97M
SCPL
12
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
$18.8M 1.82%
1,346,246
+47,027
+4% +$627K
INVZ icon
13
Innoviz Technologies
INVZ
$96.5M
$18.7M 1.81%
4,771,390
+1,388,065
+41% +$5.41M
CTLP
14
DELISTED
Cantaloupe
CTLP
$16.6M 1.6%
2,963,188
+924,709
+45% +$4.91M
APYX icon
15
Apyx Medical
APYX
$157M
$16.5M 1.59%
2,818,341
+184,338
+7% +$946K
HCVIU
16
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
$14.6M 1.41%
1,500,000
PEGR
17
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
$14.6M 1.41%
1,500,000
ET icon
18
Energy Transfer Partners
ET
$70.1B
$14.3M 1.38%
1,435,000
+280,000
+24% +$3.14M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$336M
$13.8M 1.33%
1,000,000
RBAC
20
DELISTED
RedBall Acquisition Corp.
RBAC
$12.5M 1.2%
+1,251,692
New +$12.4M
FULC icon
21
Fulcrum Therapeutics
FULC
$247M
$11.7M 1.13%
2,385,885
-1,067,486
-31% -$10.4M
ADER
22
DELISTED
26 Capital Acquisition Corp
ADER
$9.81M 0.95%
1,000,000
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$9.11M 0.88%
3,732,778
JNCE
24
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$8.62M 0.83%
2,843,149
+2,268,814
+395% +$11M
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.81B
$8.43M 0.81%
1,065,724
+343,149
+47% +$4.15M

Similar funds

Cowen and Company's Q2 2022 Portfolio in Review

As of Q2 2022, Cowen and Company held 852 positions worth $1.04B, down 0.33% from $1.04B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cowen and Company deployed $220M of net new capital in Q2 2022, opening 247 new positions and adding to 177 existing holdings. Its largest new stake was Avidity Biosciences: 2,264,150 shares worth $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 40% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Social Capital Hedosophia Holdings Corp. VI, an estimated $16.9M trimmed.

  • Cowen and Company's largest Q2 2022 buy was Avidity Biosciences: 2,264,150 shares worth $32.9M.
  • Cowen and Company added most to ARK Innovation ETF in Q2 2022, an estimated $72.6M increase.
  • Cowen and Company's biggest Q2 2022 reduction was Social Capital Hedosophia Holdings Corp. VI, cutting an estimated $16.9M.
  • Cowen and Company fully exited Rivian in Q2 2022, selling an estimated $26.8M.
  • Cowen and Company's ten largest holdings make up 44% of its $1.04B portfolio in Q2 2022.
  • Cowen and Company opened 247 new positions and closed 202 in Q2 2022.
  • Cowen and Company's portfolio value fell 0.33% quarter-over-quarter to $1.04B.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.